Renaissance Technologies Q1 2026: From AI Edges to Hard Assets

Renaissance’s biggest dollar adds are not venture-like moonshots; they are franchises that sit in the middle of secular traffic flows and capex budgets.

On the AI infrastructure side, they go hard into three pillars:

• Apple arrives as a new $780.6M position, a late but decisive embrace of the device and ecosystem layer that will capture AI at the edge.
• Nvidia is boosted by +190.0% and Broadcom by an eye-popping +89191.0% in shares, signaling a pivot toward the GPU and custom silicon vendors that actually monetize AI buildout.
• Western Digital and Verisign see increases too, showing interest in the storage and core internet plumbing that quietly scale with data and traffic.

The second leg of rising conviction is hard assets and industrial chemistry:

• Linde’s +394.8% share increase and Barrick’s +335.8% ramp, alongside adds to Kinross, Alamos and Vale, say they want leverage to industrial production, data-center build and gold as a monetary hedge.

Finally, they lean into payment and transaction rails over pure consumer internet:

• Visa, JPMorgan and MercadoLibre are all scaled up aggressively, moving Real Estate-labeled e-commerce/fintech exposure from 2.29% to 3.97% while Finance rises from 5.29% to 6.14%. The message: own the pipes that process activity rather than just the front-end apps.

Funding for these upgrades comes from exactly where you’d expect: prior-cycle winners and more fragile consumer and biotech bets.

The largest slices come from legacy AI and semiconductor exposures:

• Micron is cut by -28.2%, Intel by -25.2% and SanDisk by -33.9%, even though each sits hundreds of percent above cost. Renaissance is cashing in cyclical and legacy storage gains to pay for Nvidia, Broadcom and Apple.
• Palantir is trimmed -20.6% after a spectacular run versus cost, which reads less like a loss of faith and more like disciplined profit taking in a volatile narrative name.

Consumer and fintech provide the other main funding bucket:

• Airbnb sees a -37.7% reduction, while Carvana, Wayfair and DoorDash are either cut or only modestly increased despite deep drawdowns versus cost in some cases. That signals skepticism about a smooth consumer internet re-acceleration.
• Nu Holdings is reduced -28.4% even as they add to JPMorgan and Robinhood; they’re rotating from high-beta emerging-market fintech into more established or higher-quality financial platforms.

In healthcare, the pattern is similar: harvest the big biotech winners, recycle into steadier services and devices. United Therapeutics, Gilead, Incyte, Alkermes and Corcept are all trimmed around high gains, while UnitedHealth, Boston Scientific, Neurocrine and Medpace see fresh capital.

At the sector level, this quarter is less about wholesale reallocation and more about refining which parts of each sector they want to own.

Technology inches up from 38.84% to 39.15%, but the character of that exposure changes. They lean into semis that sit closest to AI spend (Nvidia, Broadcom) and maintain or add to software and services with durable franchises (Apple, Verisign, Adobe), while trimming memory, older storage and some frothier software like Zoom.

Healthcare’s weight slips from 22.94% to 21.29% as they recycle capital from highly successful biotech positions into managed-care and device names. The sector remains a core profit pool, but it is being tilted away from binary drug risk toward recurring-care and procedure volumes.

Basic Materials is the clearest upshift, rising to 12.93% on the back of gold miners (Barrick, Kinross, Alamos), metals (Vale) and Linde. At the same time, Energy nudges down from 3.91% to 3.42%, a quiet swap from pure hydrocarbons to metals and industrial gases that better match data-center and manufacturing intensity.

Consumer Discretionary shrinks from 12.19% to 10.12%, with online platforms and cyclical retailers providing cash for higher-conviction growth and hard-asset plays. Finance and the Real Estate bucket (home to Visa, MercadoLibre and Etsy) both rise, expressing a preference for transaction volumes and payment rails over advertising-heavy consumer internet.

Put together, this 13F paints a manager that wants to own the rails, not the stories. The rails for compute (Nvidia, Broadcom, Apple), for trade and consumption (Visa, JPMorgan, MercadoLibre), and for an inflationary backdrop (gold miners, metals, Linde).

The trims in volatile consumer internet and some high-beta fintech hint at a view that macro and rate volatility will keep discretionary spending choppy, even as AI and infrastructure capex stay robust. They’re keeping exposure to platforms like Roblox, Etsy and DoorDash, but only after sizing them against more central network nodes.

In healthcare, the mix shift toward UnitedHealth, Boston Scientific and Medpace says they still like the sector’s defensiveness and volume growth, just with less reliance on binary biotech outcomes. Biotech winners remain in the book, but now as harvested positions rather than primary growth engines.

For future quarters, this setup suggests Renaissance is positioned for an environment where AI capex, transaction volumes and industrial build-out continue, while inflation stays non-trivial and consumers remain selective. If that world persists, this portfolio is built to collect tolls at multiple chokepoints rather than bet on any single demand narrative.